Rx Import Bill Mark-Up Postponed
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Health Committee's mark-up of Sen. Judd Gregg's (R-N.H.) drug importation bill scheduled for July 21 has been postponed due to the expected signing of "BioShield" legislation by President Bush.
You may also be interested in...
BioShield II "Wild Card" Exclusivity Could Extend Up To Two Years
Two-year patent extension will not be automatic under second round of biodefense legislation, staffer for Sen. Lieberman says. A number of factors will determine the length of the "wild card" extension. Lieberman and Sen. Hatch are expected to introduce the bill in February.
BioShield II "Wild Card" Exclusivity Could Extend Up To Two Years
Two-year patent extension will not be automatic under second round of biodefense legislation, staffer for Sen. Lieberman says. A number of factors will determine the length of the "wild card" extension. Lieberman and Sen. Hatch are expected to introduce the bill in February.
Reimportation Law Unlikely This Year Despite Democratic Pressure
Senate Majority Leader Frist says he does not expect to fit Rx import language into the schedule during the session’s remaining days. The Senate Health Committee has no plans to markup a bill.